- Home
- HAYW vs TARS Comparison
HAYW vs TARS Comparison
Compare HAYW & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAYW
- TARS
- Stock Information
- Founded
- HAYW 1925
- TARS 2016
- Country
- HAYW United States
- TARS United States
- Employees
- HAYW N/A
- TARS N/A
- Industry
- HAYW Electronic Components
- TARS Medicinal Chemicals and Botanical Products
- Sector
- HAYW Technology
- TARS Health Care
- Exchange
- HAYW Nasdaq
- TARS Nasdaq
- Market Cap
- HAYW 3.3B
- TARS 2.8B
- IPO Year
- HAYW 2021
- TARS 2020
- Fundamental
- Price
- HAYW $15.78
- TARS $73.26
- Analyst Decision
- HAYW Buy
- TARS Strong Buy
- Analyst Count
- HAYW 4
- TARS 7
- Target Price
- HAYW $18.00
- TARS $69.86
- AVG Volume (30 Days)
- HAYW 2.2M
- TARS 499.8K
- Earning Date
- HAYW 10-29-2025
- TARS 11-04-2025
- Dividend Yield
- HAYW N/A
- TARS N/A
- EPS Growth
- HAYW 44.13
- TARS N/A
- EPS
- HAYW 0.62
- TARS N/A
- Revenue
- HAYW $1,099,855,000.00
- TARS $366,100,000.00
- Revenue This Year
- HAYW $6.69
- TARS $139.46
- Revenue Next Year
- HAYW $5.53
- TARS $49.91
- P/E Ratio
- HAYW $25.47
- TARS N/A
- Revenue Growth
- HAYW 9.66
- TARS 182.44
- 52 Week Low
- HAYW $11.10
- TARS $38.51
- 52 Week High
- HAYW $17.73
- TARS $76.81
- Technical
- Relative Strength Index (RSI)
- HAYW 48.43
- TARS 60.27
- Support Level
- HAYW $15.73
- TARS $65.93
- Resistance Level
- HAYW $16.41
- TARS $76.38
- Average True Range (ATR)
- HAYW 0.43
- TARS 3.00
- MACD
- HAYW -0.06
- TARS 0.15
- Stochastic Oscillator
- HAYW 21.89
- TARS 70.32
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.